Illumina (NASDAQ:ILMN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Illumina (NASDAQ:ILMN) in a research note released on Friday morning. The brokerage issued a buy rating on the life sciences company’s stock.

A number of other brokerages have also recently weighed in on ILMN. Stephens reiterated an overweight rating and set a $170.00 price target on shares of Illumina in a research report on Tuesday, May 7th. Barclays lifted their price objective on shares of Illumina from $85.00 to $100.00 and gave the company an underweight rating in a report on Wednesday, April 10th. TD Cowen dropped their price objective on shares of Illumina from $140.00 to $122.00 and set a hold rating for the company in a report on Thursday, June 6th. Jefferies Financial Group began coverage on shares of Illumina in a report on Monday, June 3rd. They issued a hold rating and a $115.00 price objective for the company. Finally, Scotiabank dropped their price objective on shares of Illumina from $185.00 to $176.00 and set a sector outperform rating for the company in a report on Monday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Hold and an average target price of $158.14.

Illumina Stock Performance

NASDAQ:ILMN opened at $108.66 on Friday. The company’s 50-day moving average price is $114.93 and its 200-day moving average price is $127.78. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The company has a market cap of $17.31 billion, a P/E ratio of -13.33 and a beta of 1.20. Illumina has a twelve month low of $89.00 and a twelve month high of $212.49.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm earned $0.08 earnings per share. Illumina’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, sell-side analysts forecast that Illumina will post 1.04 earnings per share for the current fiscal year.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bouvel Investment Partners LLC raised its position in Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after purchasing an additional 84 shares during the last quarter. STF Management LP raised its position in Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 90 shares during the last quarter. Global Retirement Partners LLC raised its position in Illumina by 12.3% in the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after purchasing an additional 94 shares during the last quarter. Gulf International Bank UK Ltd raised its position in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after purchasing an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC raised its position in Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.